Pacira Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 19, 2021, details the consummation of the acquisition of Flexion Therapeutics, Inc. ("Flexion") by Pacira Biosciences, Inc. ("Pacira"). The transaction was executed via a tender offer followed by a merger under Section 251(h) of the Delaware General Corporation Law, making Flexion a wholly-owned subsidiary of Pacira.
Key Financial Metrics and Transaction Terms
- Total Consideration: Approximately $734.3 million paid for Flexion shares and debt repayment (excluding fees, assumed cash, and potential milestone payments).
- Offer Price Structure: $8.50 per share in cash plus one Contingent Value Right (CVR) per share.
- Shares Tendered: 26,026,307 shares (51.7% of outstanding shares) were validly tendered and accepted.
- Guaranteed Deliveries: Notices received for an additional 9,526,961 shares (18.9% of outstanding shares).
- Contingent Liability: Up to $424.9 million in aggregate potential future payments if all CVR milestones are achieved by December 31, 2030.
- Liquidity Source: Pacira funded the transaction using existing cash and liquid financial resources.
Material Changes and CVR Milestones
The primary material change is the addition of Flexion's assets and liabilities to Pacira's balance sheet. The transaction includes a Contingent Value Right (CVR) agreement with the following potential cash milestones (up to $8.00 per share):
- ZILRETTA Sales Milestones:
- $1.00 per CVR upon annual net sales reaching $250.0 million.
- $2.00 per CVR upon annual net sales reaching $375.0 million.
- $3.00 per CVR upon annual net sales reaching $500.0 million.
- Regulatory Milestones:
- $1.00 per CVR upon FDA approval of a Biologics License Application (BLA) for FX201 (gene therapy).
- $1.00 per CVR upon FDA approval of a New Drug Application (NDA) for FX301.
It is possible that no milestones will be achieved, resulting in no CVR payments. Pacira is obligated to use "commercially reasonable efforts" to achieve these milestones.
Outlook, Risks, and Unusual Items
Equity Awards Treatment: All outstanding Flexion stock options and restricted stock units (RSUs) were accelerated and vested. "In-the-money" options were converted to cash and CVRs. "Out-of-the-money" options (exercise price below $9.12) were converted to rights to receive cash and CVRs contingent on future milestones. Options with exercise prices at or above $9.12 were canceled for no consideration.
Risks and Contingencies:
- Payment Uncertainty: There is no assurance that any CVR milestones will be met; payments depend on commercial success and regulatory approvals outside Pacira's full control.
- Creditor Status: CVR holders have no voting or dividend rights and rank as general unsecured creditors.
- Financial Reporting: Audited financial statements of Flexion and pro forma financial information are not included in this filing and will be submitted within 71 days.
Investor Verification Checklist
- Verify the final count of shares tendered and the total cash outflow upon settlement.
- Monitor the upcoming filing (within 71 days) for Flexion's audited financial statements and pro forma combined financial data.
- Track ZILRETTA sales performance against the $250M, $375M, and $500M annual thresholds.
- Monitor FDA regulatory timelines for FX201 and FX301 approvals.
- Review Pacira's liquidity position post-transaction to ensure capacity for potential future CVR payments.